Pharmaceutical companies have juiced US drug prices through a series of anticompetitive tactics, including product-hopping and other patent abuses that extend branded drugs’ market exclusivity periods, a staff report released today by a House committee says. The report (see here) caps a three-year investigation by the US House Committee on Oversight and